These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 27977132)
21. Mesenchymal Stem Cells Increase Hippocampal Neurogenesis and Neuronal Differentiation by Enhancing the Wnt Signaling Pathway in an Alzheimer's Disease Model. Oh SH; Kim HN; Park HJ; Shin JY; Lee PH Cell Transplant; 2015; 24(6):1097-109. PubMed ID: 24612635 [TBL] [Abstract][Full Text] [Related]
22. Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease. Zhou T; Zu G; Zhang X; Wang X; Li S; Gong X; Liang Z; Zhao J Neuropharmacology; 2016 Feb; 101():480-9. PubMed ID: 26525190 [TBL] [Abstract][Full Text] [Related]
23. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats. El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042 [TBL] [Abstract][Full Text] [Related]
24. Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats. Bonato JM; Bassani TB; Milani H; Vital MABF; de Oliveira RMW Exp Neurol; 2018 Feb; 300():188-200. PubMed ID: 29162435 [TBL] [Abstract][Full Text] [Related]
25. Sevoflurane affects neurogenesis through cell cycle arrest via inhibiting wnt/β-catenin signaling pathway in mouse neural stem cells. Liu S; Fang F; Song R; Gao X; Jiang M; Cang J Life Sci; 2018 Sep; 209():34-42. PubMed ID: 30071197 [TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease. Chiu WH; Depboylu C; Hermanns G; Maurer L; Windolph A; Oertel WH; Ries V; Höglinger GU Neuropharmacology; 2015 Aug; 95():367-76. PubMed ID: 25839898 [TBL] [Abstract][Full Text] [Related]
27. Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease. Kohl Z; Ben Abdallah N; Vogelgsang J; Tischer L; Deusser J; Amato D; Anderson S; Müller CP; Riess O; Masliah E; Nuber S; Winkler J Neurobiol Dis; 2016 Jan; 85():206-217. PubMed ID: 26523794 [TBL] [Abstract][Full Text] [Related]
28. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. Kadota T; Shingo T; Yasuhara T; Tajiri N; Kondo A; Morimoto T; Yuan WJ; Wang F; Baba T; Tokunaga K; Miyoshi Y; Date I Brain Res; 2009 Feb; 1254():120-7. PubMed ID: 19101524 [TBL] [Abstract][Full Text] [Related]
29. Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice. Chen L; Cheng L; Wei X; Yuan Z; Wu Y; Wang S; Ren Z; Liu X; Liu H Neurochem Res; 2017 Apr; 42(4):1141-1150. PubMed ID: 28005221 [TBL] [Abstract][Full Text] [Related]
30. Modelling the dopamine and noradrenergic cell loss that occurs in Parkinson's disease and the impact on hippocampal neurogenesis. Ermine CM; Wright JL; Frausin S; Kauhausen JA; Parish CL; Stanic D; Thompson LH Hippocampus; 2018 May; 28(5):327-337. PubMed ID: 29431270 [TBL] [Abstract][Full Text] [Related]
31. Promoting neurogenesis via Wnt/β-catenin signaling pathway accounts for the neurorestorative effects of morroniside against cerebral ischemia injury. Sun FL; Wang W; Zuo W; Xue JL; Xu JD; Ai HX; Zhang L; Wang XM; Ji XM Eur J Pharmacol; 2014 Sep; 738():214-21. PubMed ID: 24876057 [TBL] [Abstract][Full Text] [Related]
32. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model. Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506 [TBL] [Abstract][Full Text] [Related]
33. Selenomethionine promoted hippocampal neurogenesis via the PI3K-Akt-GSK3β-Wnt pathway in a mouse model of Alzheimer's disease. Zheng R; Zhang ZH; Chen C; Chen Y; Jia SZ; Liu Q; Ni JZ; Song GL Biochem Biophys Res Commun; 2017 Mar; 485(1):6-15. PubMed ID: 28109879 [TBL] [Abstract][Full Text] [Related]
34. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549 [TBL] [Abstract][Full Text] [Related]
38. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868 [TBL] [Abstract][Full Text] [Related]
39. Protective Effect of Curcumin Against Oxidative Stress-Induced Injury in Rats with Parkinson's Disease Through the Wnt/ β-Catenin Signaling Pathway. Wang YL; Ju B; Zhang YZ; Yin HL; Liu YJ; Wang SS; Zeng ZL; Yang XP; Wang HT; Li JF Cell Physiol Biochem; 2017; 43(6):2226-2241. PubMed ID: 29069652 [TBL] [Abstract][Full Text] [Related]
40. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]